1、 On December 13, the National Health Insurance Bureau announced the results of the adjustment of the national medical insurance list in 2023. A total of 126 drugs were added to the national medical insurance drug list, including the first monoclonal antibody subcutaneous preparation Herceptin? (Trastuzumab Injection (Subcutaneous Injection), also included in the new medical insurance list, became the first subcutaneous targeted drug. What new drugs for breast cancer treatment are included in the latest medical insurance catalogue this year, and what benefits and changes will these new drugs bring to both doctors and patients? For breast cancer prevention and "chronic disease management", what prevention and management measures should women take? On December 27-29, 2023, our reporter launched online and offline in-depth discussions and exchanges with several Guangdong clinical treatment experts on hot topics of breast cancer prevention and treatment. （1） Interview expert: Wang Xi 1. Expert position: Chief Physician of the Cancer Prevention and Treatment Center of Sun Yat sen University 2. Expert introduction: Doctor of Medicine and Postdoctoral fellow; Chief expert of breast cancer single disease in Cancer Center of Sun Yat sen University; Director of Breast Surgery; Professor, chief physician, doctoral supervisor; Member of breast cancer Professional Committee of China Anti Cancer Association, Chairman of breast cancer Professional Committee of Guangdong Anti Cancer Association, Chairman of Breast Cancer Branch of Guangdong Precision Medical Application Society, Chairman of breast cancer Expert Committee of Guangdong Cancer Medical Quality Control Center. He is good at research on comprehensive treatment of breast cancer; Research on sentinel lymph node biopsy; Series studies on triple negative breast cancer; The study of breast reconstruction after breast cancer surgery. Hosted 4 national natural science projects and multiple provincial-level scientific research projects, and published over 30 SCI papers. One article by the first author of JAMA's main journal (SCI45.5). （2） Interview expert: Shi Fujun 1. Expert title: Director of Breast Surgery of the Pearl River Hospital of Southern Medical University 2. Expert introduction: Postdoctoral surgeon, master's supervisor, returned scholar in the United States, member of the American Society of Breast Surgeons (ASBrS), vice chairman of the Breast Minimally Invasive Reconstruction Special Committee of Guangdong Grass roots Medical Association, vice chairman of the Breast Cancer Branch of Guangdong Precision Medical Application Association, vice chairman of the Day Medical Professional Committee of Guangdong Grass roots Medical Association, standing member of the Breast Disease Branch of Guangdong Medical Association, standing member of the Breast Reconstruction and Aesthetics Professional Committee of Guangdong Health Management Association, member of the Breast Specialist Branch of Guangdong Medical Association, Journal of Practical Medicine and World Journal al of Surgical Oncology. He has been engaged in medical, teaching and scientific research for more than 20 years, has a comprehensive understanding of the diagnosis and treatment of common diseases in breast surgery, and has rich clinical experience in breast cancer, benign breast tumors, male breast development, etc. He is especially good at breast conserving reconstruction surgery for breast cancer, modified endoscopic radical surgery for breast cancer, and endoscopic resection of benign breast tumors. He has accumulated rich experience in comprehensive treatment of breast cancer and won honorary titles such as "Young and Middle aged Physicians with Strength" (in the field of breast) selected by Guangzhou Daily. Outstanding teaching performance, one of the first batch of all English teaching teachers at Southern Medical University, and has won national level awards multiple times